{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:46:05Z","timestamp":1791751565040,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.blre.2009.11.001","type":"journal-article","created":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T00:11:48Z","timestamp":1260144708000},"page":"11-16","source":"Crossref","is-referenced-by-count":11,"title":["Inhibitory anti-ADAMTS 13 antibodies: Measurement and clinical application"],"prefix":"10.1016","volume":"24","author":[{"given":"Marie","family":"Scully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2009.11.001_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.001_bib2","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.blre.2009.11.001_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.05217.x","article-title":"von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Peyvandi","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.001_bib10","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z","article-title":"United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange","volume":"13","author":"Bandarenko","year":"1998","journal-title":"J Clin Apher"},{"key":"10.1016\/j.blre.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/0003-4819-122-8-199504150-00002","article-title":"Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group","volume":"122","author":"Shumak","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib17","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1538-7836.2006.02025.x","article-title":"Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo","volume":"4","author":"Shelat","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib18","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2141.2005.05837.x","article-title":"Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura","volume":"132","author":"Coppo","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2005.05512.x","article-title":"The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine","volume":"129","author":"Bohm","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/j.1538-7836.2006.02164.x","article-title":"Multiple B-cell clones producing antibodies directed to the spacer and disintegrin\/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Luken","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1538-7836.2008.03250.x","article-title":"VH1\u201369 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Pos","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2009.11.001_bib27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1055\/s-2005-925476","article-title":"Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?","volume":"31","author":"Willis","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2009.11.001_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2141.2008.07317.x","article-title":"Treating TTP\/HUS with plasma exchange: a single centre\u2019s 25-year experience","volume":"143","author":"Forzley","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.11.001_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.transci.2005.08.010","article-title":"Daily plasma-exchange for life-threatening class I HELLP syndrome with prevalent pulmonary involvement","volume":"34","author":"Del Fante","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2009.11.001_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<57::AID-AJH10>3.0.CO;2-6","article-title":"Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine","volume":"57","author":"Pasquale","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2009.11.001_bib32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","article-title":"An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"136","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-0609.2007.00832.x","article-title":"Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura","volume":"78","author":"Ahmad","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jca.20172","article-title":"Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature","volume":"23","author":"Jasti","year":"2008","journal-title":"J Clin Apher"},{"key":"10.1016\/j.blre.2009.11.001_bib37","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1160\/TH07-12-0753","article-title":"Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies","volume":"101","author":"Bresin","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib39","first-page":"215","article-title":"Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab","volume":"4","author":"Herbei","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.blre.2009.11.001_bib40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","article-title":"Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia","volume":"97","author":"Heidel","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib41","first-page":"965","article-title":"Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura","volume":"126","author":"Boctor","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2009.11.001_bib42","first-page":"210","article-title":"Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"4","author":"Hull","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.blre.2009.11.001_bib43","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/j.1537-2995.2005.00560.x","article-title":"Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab","volume":"45","author":"Millward","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2009.11.001_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajh.10204","article-title":"Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab","volume":"71","author":"Chemnitz","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2009.11.001_bib45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","article-title":"Rituximab therapy for refractory thrombotic thrombocytopenic purpura","volume":"28","author":"Gutterman","year":"2002","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2009.11.001_bib46","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2004.00678.x","article-title":"Rituximab in patients with refractory thrombotic thrombocytopenic purpura","volume":"2","author":"Sallah","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2009.11.001_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.20166","article-title":"Rituximab for treatment of refractory\/relapsing thrombotic thrombocytopenic purpura (TTP)","volume":"77","author":"Ahmad","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2009.11.001_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2141.2004.04836.x","article-title":"Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature","volume":"124","author":"Yomtovian","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.001_bib49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","article-title":"Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura","volume":"84","author":"Reddy","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2009.11.001_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-12-4885","article-title":"Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report","author":"Galbusera","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.001_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ajh.20243","article-title":"Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases","volume":"78","author":"Koulova","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2009.11.001_bib52","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1309\/RLNM-J01W-BJRN-LH03","article-title":"Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP","volume":"125","author":"Darabi","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2009.11.001_bib53","first-page":"1194","article-title":"Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease","volume":"33","author":"Niewold","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2009.11.001_bib54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jca.20113","article-title":"Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura","volume":"22","author":"Patino","year":"2007","journal-title":"J Clin Apher"},{"key":"10.1016\/j.blre.2009.11.001_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1445-5994.2007.01338.x","article-title":"Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange","volume":"37","author":"Chow","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.blre.2009.11.001_bib56","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s10067-007-0631-0","article-title":"Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment","volume":"26","author":"Kameda","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.blre.2009.11.001_bib57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-007-0384-5","article-title":"Long-term remission in a patient with refractory thrombotic thrombocytopenic purpura treated with rituximab and plasma exchange","volume":"87","author":"Basquiera","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2009.11.001_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1160\/TH08-02-0089","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab","volume":"100","author":"Hagel","year":"2008","journal-title":"Thromb Haemost"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X09000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X09000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T01:16:32Z","timestamp":1710724592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X09000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0268960X09000666"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2009.11.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}